The Oncology Institute, Inc. (TOI)
NASDAQ: TOI · Real-Time Price · USD
0.235
-0.029 (-10.84%)
At close: Nov 14, 2024, 4:00 PM
0.260
+0.025 (10.54%)
After-hours: Nov 14, 2024, 7:58 PM EST
The Oncology Institute Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 |
| Revenue | 378.93 | 324.24 | 252.48 | 203 | 187.52 | 155.41 | Upgrade
|
| Revenue Growth (YoY) | 22.29% | 28.42% | 24.37% | 8.26% | 20.66% | 37.33% | Upgrade
|
| Cost of Revenue | 325.19 | 264.67 | 200.39 | 162.16 | 150.64 | 125.46 | Upgrade
|
| Gross Profit | 53.74 | 59.57 | 52.09 | 40.85 | 36.88 | 29.94 | Upgrade
|
| Selling, General & Admin | 111.06 | 113.85 | 119.69 | 82.89 | 41.52 | 29.64 | Upgrade
|
| Operating Expenses | 117.22 | 119.72 | 124.1 | 86.23 | 44.7 | 32.59 | Upgrade
|
| Operating Income | -63.48 | -60.15 | -72.01 | -45.38 | -7.82 | -2.64 | Upgrade
|
| Interest Expense | -8.27 | -6.78 | -4.08 | -0.32 | -0.35 | -0 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.95 | -0.35 | 25.9 | 3.71 | -8.72 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | -70.8 | -67.28 | -50.19 | -41.99 | -16.89 | -2.64 | Upgrade
|
| Merger & Restructuring Charges | - | - | - | -0.48 | 1.1 | - | Upgrade
|
| Impairment of Goodwill | - | -16.87 | -9.94 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Investments | 0.24 | 0.24 | 0.64 | - | - | - | Upgrade
|
| Other Unusual Items | 0.01 | 0.8 | 59.4 | 30.87 | 0.98 | - | Upgrade
|
| Pretax Income | -70.55 | -83.1 | -0.09 | -11.6 | -14.82 | -2.64 | Upgrade
|
| Income Tax Expense | -0.31 | -0.04 | -0.24 | -0.67 | -0.49 | 1.38 | Upgrade
|
| Net Income | -70.24 | -83.07 | 0.15 | -10.93 | -14.32 | -4.02 | Upgrade
|
| Preferred Dividends & Other Adjustments | -15.19 | -15.19 | 0.08 | -0.3 | - | - | Upgrade
|
| Net Income to Common | -55.04 | -67.88 | 0.07 | -10.63 | -14.32 | -4.02 | Upgrade
|
| Shares Outstanding (Basic) | 75 | 74 | 73 | 66 | 59 | - | Upgrade
|
| Shares Outstanding (Diluted) | 75 | 74 | 81 | 66 | 59 | - | Upgrade
|
| Shares Change (YoY) | 1.59% | -8.51% | 21.70% | 12.03% | - | - | Upgrade
|
| EPS (Basic) | -0.74 | -0.92 | 0.00 | -0.16 | -0.24 | - | Upgrade
|
| EPS (Diluted) | -0.77 | -0.92 | -0.21 | -0.16 | -0.24 | - | Upgrade
|
| Free Cash Flow | -37.51 | -40.88 | -67.29 | -35.53 | -0.69 | 2.41 | Upgrade
|
| Free Cash Flow Per Share | -0.50 | -0.55 | -0.83 | -0.54 | -0.01 | - | Upgrade
|
| Gross Margin | 14.18% | 18.37% | 20.63% | 20.12% | 19.67% | 19.27% | Upgrade
|
| Operating Margin | -16.75% | -18.55% | -28.52% | -22.36% | -4.17% | -1.70% | Upgrade
|
| Profit Margin | -14.53% | -20.93% | 0.03% | -5.24% | -7.64% | -2.59% | Upgrade
|
| Free Cash Flow Margin | -9.90% | -12.61% | -26.65% | -17.50% | -0.37% | 1.55% | Upgrade
|
| EBITDA | -57.32 | -54.28 | -67.6 | -42.04 | -4.65 | 0.3 | Upgrade
|
| EBITDA Margin | -15.13% | -16.74% | -26.77% | -20.71% | -2.48% | 0.19% | Upgrade
|
| D&A For EBITDA | 6.16 | 5.87 | 4.41 | 3.34 | 3.18 | 2.94 | Upgrade
|
| EBIT | -63.48 | -60.15 | -72.01 | -45.38 | -7.82 | -2.64 | Upgrade
|
| EBIT Margin | -16.75% | -18.55% | -28.52% | -22.36% | -4.17% | -1.70% | Upgrade
|
| Revenue as Reported | 378.93 | 324.24 | 252.48 | 203 | 187.52 | 155.41 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.